Today: 20 March 2026
Subscribe
Browse Category

Pharmaceuticals 22 August 2025 - 11 October 2025

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca (AZN) Stock Skyrockets: $50B U.S. Gamble, Trump Pricing Deal & Analyst Forecasts

AstraZeneca shares traded near £127.82 ($85 ADR) on Oct. 10, 2025, close to a 52-week high after a U.S. NYSE listing and a $4.5 billion Virginia plant announcement. Market cap stands at $264 billion, with 2024 revenue of $54.1 billion, up 18%. The company agreed to provide U.S. Medicaid with its lowest global drug prices. Shares have rallied over 10% since late September.
11 October 2025
···
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics shares surged over 30% to nearly $89 on October 10, 2025, after reports that Johnson & Johnson is in talks to acquire the company. Trading was briefly halted due to volatility. The company, valued at about $5.4 billion, recently announced positive trial results for its lead drugs and secured major partnerships with J&J and Takeda.
11 October 2025
·····
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk will acquire Akero Therapeutics for up to $5.2 billion, paying $54 per share in cash plus a potential $6 per share if Akero’s lead drug wins U.S. approval by 2031. Akero’s efruxifermin, in Phase 3 trials for fatty liver disease, has shown reversal of liver fibrosis in mid-stage studies. Akero shares jumped 19% on the news, while Novo shares were little changed. The deal is expected to close by year-end.
9 October 2025
··
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions

Acurx Pharmaceuticals shares have fallen about 90% from their 52-week high, trading near $4.30 after a 1-for-20 reverse split in August. The stock briefly rallied in late September after the European Medicines Agency issued a positive opinion on its pediatric plan for ibezapolstat. Acurx remains pre-revenue with $6.1 million in cash at Q2’s end and faces additional funding needs for Phase 3 trials.
8 October 2025
·
Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Why Puerto Rico Could Reclaim Its Status as a Pharmaceutical Powerhouse: The Hidden Opportunity Behind Reshoring

Manufacturing accounts for up to 47% of Puerto Rico’s GDP and delivered over $50 billion in output in 2020, supporting more than 220,000 jobs. Amgen is investing $926.7 million in Juncos, creating nearly 3,000 jobs. At least seven manufacturers have announced expansions since 2020, with $220 million in new commitments. The island faces competition, power outages, and workforce shortages.
6 October 2025
Cidara Therapeutics (CDTX) Surges on Accelerated Flu Drug Trial – Key Updates for Investors

Cidara Therapeutics (NASDAQ: CDTX) 2025 Investment Analysis – Will This Anti‑Flu Innovator Keep Soaring?

Cidara Therapeutics’ stock rose 279% year-to-date, closing at $101.99 on Oct. 3, 2025, up from $26.88 at the start of the year. The company’s CD388 drug showed 76% protection against flu in a Phase 2b trial. BARDA awarded up to $339 million in October for manufacturing and clinical development. As of June, Cidara held $516.9 million in cash.
4 October 2025
··
Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus Eyedrop Breakthrough Sends Stock Soaring: 10.9% Rally and Counting

Tarsus (NASDAQ:TARS) surged 10.9% to $65.17 on Oct. 3, 2025, after reporting Q2 net product revenue of $102.7 million, up 152% year-over-year, driven by XDEMVY eyedrop sales. Shares have climbed 31% in the past month and 84% over the year. Wall Street consensus rates the stock a “Buy,” with average 12-month targets near $71. Losses are narrowing as sales rise and cash reserves remain strong.
3 October 2025
···
Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead?

SRPT closed at $19.57 on Oct 2, up 6.8% for the day and nearly 16% over the past month, but remains down about 82% year-to-date. The company restructured in July, cutting 500 jobs and pausing some gene therapy trials after FDA safety concerns. Sarepta resumed shipments of Elevidys for ambulatory DMD patients following FDA guidance. Analyst consensus is “Hold,” with price targets ranging from $14 to $39.
2 October 2025
··
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

President Trump will announce “TrumpRx,” a federal website allowing Americans to buy discounted prescription drugs directly. The White House secured a deal with Pfizer to cut U.S. prices on several medications and invest $70 billion in domestic research. Drugmakers responded with new direct-sales programs and pledged $500 billion in U.S. investments. Some experts warn price controls could limit innovation and shift higher costs overseas.
30 September 2025
·
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Pfizer shares closed near a 52-week low at $24.40 on Sept. 30, 2025, despite Q2 revenue of $14.7 billion and adjusted EPS of $0.78, both above expectations. The company raised full-year EPS guidance and announced a $4.9 billion deal to acquire obesity drugmaker Metsera. President Trump unveiled a pact for Pfizer to cut U.S. drug prices and sell through a new TrumpRx site. FDA approved Pfizer’s updated COVID-19 vaccine for high-risk groups.
30 September 2025
··
European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European Stocks Rally on Pharma Shakeups, Tech Surge – What’s Next?

European stocks closed higher Monday, with the FTSE 100 up 0.5% and the STOXX 600 gaining 0.2% as healthcare and tech outperformed. GSK surged 3.3% after CEO Emma Walmsley’s exit was announced; AstraZeneca rose 1.3% on plans for a New York listing. Lufthansa said it will cut 4,000 jobs. Oil fell 0.6% on resumed Iraqi Kurdish exports and OPEC+ supply news; gold hit a record $3,812 an ounce.
29 September 2025
·······
Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics (CRNX) Stock Skyrockets on FDA Approval – Full 2025 Investor Update

Crinetics Pharmaceuticals shares surged 28% to around $46 on Sept. 26 after the FDA approved its first drug, Palsonify, for acromegaly. Trading volume spiked nearly tenfold amid heavy short-covering. The company plans to launch Palsonify in October at a $290,000 annual list price. Crinetics holds $1.2 billion in cash and no debt, with analysts raising price targets following the approval.
26 September 2025
··
Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

Scholar Rock (SRRK) Just Hit a Regulatory Speed Bump—But the Long‑Term Muscle‑Building Story Still Has Legs

The FDA issued a Complete Response Letter for Scholar Rock’s apitegromab on Sept. 23, citing only manufacturing issues at a third-party Indiana plant. Shares fell but analysts, including BMO and Leerink, maintained bullish outlooks, expecting a quick resolution. The EMA review continues, with a possible EU launch in late 2026. Scholar Rock reported $295 million in cash as of June 30.
26 September 2025
··
Trump’s Tariff Tsunami: 100% Drug Tax and New Import Levies Rock Global Trade

Trump’s Tariff Tsunami: 100% Drug Tax and New Import Levies Rock Global Trade

President Donald Trump will impose a 100% tariff on branded and patented pharmaceutical imports starting October 1, unless manufacturers have begun building U.S. plants. New tariffs of 25% on heavy-duty trucks, 50% on cabinets, and 30% on upholstered furniture also take effect that day. Generic drugs are exempt. The EU and Japan say existing trade deals cap their pharma tariffs at 15%.
26 September 2025
·
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······
COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

COVID Booster Shocker, Pharma Mega-Deals & Alzheimer’s Breakthroughs – Global Health Roundup (Aug 28–29, 2025)

The FDA approved updated COVID-19 boosters from Pfizer and Moderna but restricted them to seniors and high-risk groups, excluding healthy children. Infectious disease experts warned the move could leave millions unprotected. The CDC director was fired after refusing to follow anti-vaccine directives, triggering mass resignations among top officials.
29 August 2025
·
Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Eli Lilly’s oral weight-loss drug orforglipron cut body weight by up to 10.5% in a Phase 3 trial for obese diabetics, with all doses meeting primary endpoints over 72 weeks. The FDA granted full approval to Precigen’s Papzimeos, the first gene therapy for adult recurrent respiratory papillomatosis. AbbVie agreed to acquire a psychedelic-based depression drug from Gilgamesh Pharmaceuticals in a deal worth up to $1.2 billion.
27 August 2025
·····
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

The FDA approved Ionis Pharmaceuticals’ Dawnzera as the first RNA-targeted therapy to prevent hereditary angioedema attacks, priced at about $57,462 per dose. AbbVie’s Rinvoq met key endpoints in a second Phase 3 alopecia areata trial, while Scholar Rock’s apitegromab showed significant motor gains in spinal muscular atrophy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million.
23 August 2025
·······
Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

The FDA approved Ionis’s Dawnzera for hereditary angioedema and Precigen’s Papzimeos for recurrent respiratory papillomatosis, marking a first for viral immunotherapy. Gilead’s Kite Pharma will acquire Interius BioTherapeutics for $350 million. Johnson & Johnson announced a $2 billion biomanufacturing facility in North Carolina. Apollo Hospitals’ managing director sold a $170 million stake in a major block trade.
22 August 2025
·····
1 … 35 36 37 38

Stock Market Today

  • Cocoa Prices Fall on Strong Dollar and Improved West African Supply
    March 20, 2026, 2:22 PM EDT. Cocoa prices dropped sharply as May ICE NY cocoa fell 1.86% to a two-week low, pressured by a stronger U.S. dollar and improved supply prospects. Consistent rains in Ivory Coast and Ghana have boosted cocoa pod development, easing supply concerns. ICE cocoa inventories are at a 7.5-month high of 2.31 million bags, reflecting ample stockpiles. Despite recent demand signals with local grinders in Ivory Coast increasing contract purchases, price cuts by Ghana and Ivory Coast farmers-major suppliers producing over half the world's cocoa-limit price gains. Additional pressure comes from weak global demand evidenced by falling sales volumes and reduced cocoa grinding in key regions including Europe and Asia. Meanwhile, higher Nigerian exports further soften prices.
Go toTop